Coherus BioSciences Inc.

Coherus Oncology, Inc. leverages its biosimilar pipeline—UDOENYCA, YUSIMRY—and next‑generation immunotherapies (LOQTORZI, toripalimab co‑development) to capture U.S. oncology and biosimilars markets.

Headquarters: United States (USA)

Coherus BioSciences Inc. Logo
Company Profile
  • Employees: 158
  • HQ: Redwood City
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
CHRS Coherus BioSciences Inc.
Cap: 0.2B | P/E: 3.2
EQUITY NGM USD US19249H1032 Active
📈
Home Login